Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
- PMID: 23323151
- PMCID: PMC3539279
- DOI: 10.1177/1758834012469430
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
Similar articles
-
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049. Ther Adv Med Oncol. 2012. PMID: 22754590 Free PMC article.
-
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.J Surg Oncol. 2002 Oct;81(2):87-92. doi: 10.1002/jso.10137. J Surg Oncol. 2002. PMID: 12355409
-
Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.Chemotherapy. 2007;53(6):442-5. doi: 10.1159/000110016. Epub 2007 Oct 22. Chemotherapy. 2007. PMID: 17952005
-
UFT in the treatment of colorectal and breast cancer.Oncology (Williston Park). 2001 Jan;15(1 Suppl 2):49-56. Oncology (Williston Park). 2001. PMID: 11219978 Review.
-
Uracil-tegafur in gastric carcinoma: a comprehensive review.J Clin Oncol. 1998 Aug;16(8):2877-85. doi: 10.1200/JCO.1998.16.8.2877. J Clin Oncol. 1998. PMID: 9704742 Review.
Cited by
-
Germline oncopharmacogenetics, a promising field in cancer therapy.Cell Oncol (Dordr). 2015 Feb;38(1):65-89. doi: 10.1007/s13402-014-0214-4. Epub 2015 Jan 9. Cell Oncol (Dordr). 2015. PMID: 25573079 Review.
-
The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.Pathol Oncol Res. 2020 Jan;26(1):121-131. doi: 10.1007/s12253-018-00563-3. Epub 2018 Dec 5. Pathol Oncol Res. 2020. PMID: 30519982
References
-
- Carmichael J., Popiela T., Radstone D., Falk S., Borner M., Oza A., et al. (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627 - PubMed
-
- Deenen M., Terpstra W., Cats A., Boot H., Schellens J. (2010) Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 153: 767–768 - PubMed
-
- Douillard J., Hoff P., Skillings J., Eisenberg P., Davidson N., Harper P., et al. (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 17: 3605–3616 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources